Abstract
Direct mutation analysis is the major method for glutaric acidemia I (GA-I) prenatal diagnosis, while systemic application of a biochemical strategy is rare. We describe our experiences with metabolite measurement together with mutation analysis in GA-I prenatal diagnosis at a single center over 10 years. The data of genetic analysis and metabolite measurement using gas chromatography/mass spectrometry(GC/MS) and tandem mass spectrometry(MS/MS) in amniotic fluid samples of 44 fetuses from 42 GA-I families referred to our center from 2009 to 2019 were retrospectively analyzed. Among these 44 fetuses, genetic and biochemical results were both available in 39 fetuses. Of these, 6 fetuses were judged as affected and 33 fetuses as unaffected by mutation analysis. The levels of glutarylcarnitine (C5DC), C5DC/octanoylcarnitine (C8), and glutaric acid in the supernatant of amniotic fluid from affected fetuses were significantly higher than those in unaffected fetuses [1.73μmol/L (0.89–4.19) vs. 0.16μmol/L (0.06–0.37), 26.26 (12.4–55.55) vs. 2.23 (1.04–8.44), and 103.94 mmol/mol creatinine (30.37–148.31) vs. 1.01mmol/mol creatinine (0–9.81), respectively; all P < 0.0001]. Among all families, two were found to have one causative mutation in the proband, in four pregnancies from these two families, three fetuses were judged as “unaffected” and one was judged as “affected” according to metabolites results. Postnatal follow-up showed a normal phenotype in all unaffected fetuses judged by mutation or metabolite analysis. C5DC, C5DC/C8, and glutaric acid levels in the supernatant of amniotic fluid showed significant differences and no overlap between the affected and unaffected fetuses. Biochemical strategy could be implemented as a quick and convenient method for the prenatal diagnosis of GA-I.
Highlights
Glutaric acidemia I (GA-I) is an autosomal recessive metabolic disorder of lysine, hydroxylysine, and tryptophan metabolism caused by a deficiency of the Glutaryl-CoA Dehydrogenase (GCDH) enzyme (Hedlund et al, 2006)
Various methods have been reported for the prenatal diagnosis of glutaric acidemia I (GA-I), including using a biochemical strategy to measure the glutaric acid level and GCDH activity in amniotic or chorionic villus sampling (Goodman et al, 1980; Christensen, 1994) and genetic analyses to directly screen pathogenic mutations identified in the proband (Busquets et al, 1998, 2000; Lin et al, 2002; Peng et al, 2018)
We describe our experiences in the prenatal diagnosis of GA-I by measurement of metabolites in the supernatant of the amniotic fluid together with direct mutation analysis in amniotic sampling in 44 high-risk pregnancies
Summary
Glutaric acidemia I (GA-I) is an autosomal recessive metabolic disorder of lysine, hydroxylysine, and tryptophan metabolism caused by a deficiency of the Glutaryl-CoA Dehydrogenase (GCDH) enzyme (Hedlund et al, 2006). Prenatal Diagnosis of GA-I in 42 Families acid excretion of glutaric acid and 3-hydroxyglutaric acid in urine and elevated glutarylcarnitine (C5DC) in plasma. Various methods have been reported for the prenatal diagnosis of GA-I, including using a biochemical strategy to measure the glutaric acid level and GCDH activity in amniotic or chorionic villus sampling (Goodman et al, 1980; Christensen, 1994) and genetic analyses to directly screen pathogenic mutations identified in the proband (Busquets et al, 1998, 2000; Lin et al, 2002; Peng et al, 2018). It is difficult to make a precise prenatal diagnosis based on only one method
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
